Tema Etfs LLC Invests $158,000 in Celcuity, Inc. $CELC

Key Points

• Tema Etfs LLC has acquired a new position in Celcuity, Inc., purchasing 15,619 shares valued at approximately $158,000 during the first quarter of 2023.
• Insider transactions were noted as Director David Dalvey sold 100,000 shares at an average price of $43.98, reducing his position by 44.44%.
• Analysts have mixed opinions on Celcuity, with some raising target prices; however, the stock's average target price currently stands at $56.50 with a consensus "buy" rating.

Tema Etfs LLC bought a new stake in shares of Celcuity, Inc. (NASDAQ:CELC - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 15,619 shares of the company's stock, valued at approximately $158,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Aquatic Capital Management LLC purchased a new position in shares of Celcuity during the 4th quarter valued at approximately $50,000. Focus Financial Network Inc. purchased a new position in shares of Celcuity during the 1st quarter valued at approximately $108,000. Perkins Capital Management Inc. purchased a new position in shares of Celcuity during the 1st quarter valued at approximately $115,000. GAMMA Investing LLC lifted its position in shares of Celcuity by 1,237.4% during the 1st quarter. GAMMA Investing LLC now owns 1,324 shares of the company's stock valued at $131,000 after buying an additional 1,225 shares in the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Celcuity during the 4th quarter valued at approximately $142,000. Hedge funds and other institutional investors own 63.33% of the company's stock.

Insider Activity at Celcuity

In other news, Director David Dalvey sold 100,000 shares of Celcuity stock in a transaction on Monday, July 28th. The stock was sold at an average price of $43.98, for a total transaction of $4,398,000.00. Following the transaction, the director owned 125,000 shares in the company, valued at $5,497,500. The trade was a 44.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 15.78% of the stock is currently owned by corporate insiders.

Celcuity Price Performance

CELC stock traded up $2.48 during midday trading on Tuesday, reaching $53.71. The stock had a trading volume of 405,920 shares, compared to its average volume of 602,278. Celcuity, Inc. has a 52-week low of $7.57 and a 52-week high of $55.44. The company has a current ratio of 4.58, a quick ratio of 4.58 and a debt-to-equity ratio of 2.24. The company's fifty day simple moving average is $30.93 and its 200 day simple moving average is $17.76. The company has a market cap of $2.28 billion, a price-to-earnings ratio of -15.57 and a beta of 0.72.

Celcuity (NASDAQ:CELC - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.14). As a group, sell-side analysts predict that Celcuity, Inc. will post -2.62 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on CELC. Needham & Company LLC decreased their target price on Celcuity from $74.00 to $70.00 and set a "buy" rating on the stock in a research report on Friday, August 15th. HC Wainwright raised their price objective on Celcuity from $50.00 to $66.00 and gave the company a "buy" rating in a report on Monday, August 18th. Stifel Nicolaus assumed coverage on Celcuity in a report on Tuesday, July 1st. They issued a "buy" rating and a $30.00 price objective on the stock. Finally, Leerink Partners raised their price objective on Celcuity from $28.00 to $60.00 and gave the company an "outperform" rating in a report on Monday, July 28th. Four analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $56.50.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.